Vimta Labs Limited
Registered Office
142, IDA Phase II, Cherlapally
Hyderabad-500 051, Telangana, India
T : +91 40 2726 4141
F : +91 40 2726 3657

Vimta
Driven by Quality. Inspired by Science.

VLL\SE\034\2026-27
Date: 20.07.2026

B S E Limited, P J Towers, Dalal Street, Mumbai - 400001. Scrip Code : 524394	National Stock Exchange of India Limited, "Exchange Plaza", Bandra, Kurla Complex, Bandra (E), Mumbai – 400051. Trading Symbol: VIMTALABS

Dear Sir/Madam,

Sub – Press Release – Unaudited Financial Results – 30th June 2026.

With reference to the subject cited above and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release regarding the announcement of the Unaudited Financial Results for the first quarter ended 30th June 2026.

This is for your information and records.

Thanking you,

For VIMTA LABS LIMITED

SUJANI VASIREDDI
Digitally signed by SUJANI VASIREDDI
Date: 2026.07.20 15:16:23 +05'30'

VIMTA LABS LIMITED HYDERABAD-51

Sujani Vasireddi
Company Secretary and Compliance Officer

Encl: as above.

PRESS RELEASE
For Immediate dissemination

Driven by Quality. Inspired by Science.

Vimta Labs Limited Q1 FY27 Results

Q1 FY27 Total Income at Rs. 1,129 Mn, up 13.7% YoY
EBITDA margins at 36.4%; PAT margin at 18.6%

Hyderabad, July 20, 2026: Vimta Labs Limited (VIMTA) (BSE: 524394, NSE: VIMTALABS), India's leading Contract Research and Testing Organisation, has announced its financial results for the quarter ended June 30, 2026.

Financial Results – Q1 FY27:

Particulars (₹ Mn)	Q1 FY27	Q4 FY26	QoQ(%)	Q1 FY26	YoY (%)
Total Income	1,129	1,120	0.8%	993	13.7%
EBITDA (including other income)	411	421	-2.4%	354	16.0%
EBITDA Margin	*36.4%*	*37.6%*		*35.7%*	
PAT	210	211	-0.3%	189	11.4%
PAT Margin	*18.6%*	*18.9%*		*19.0%*	
Basic EPS	4.7	4.7	-0.5%	4.2	11.0%

Commenting on the results, Ms. Harita Vasireddi, Managing Director, Vimta Labs Limited, said: *"Vimta Labs delivered another strong quarter, with total income of ₹1,129 Mn, up 13.7% YoY. Our Pharmaceutical Research and Testing Services business recorded healthy traction during the quarter. While ongoing global uncertainties continued to impact the Food Testing division, the business is progressively offsetting these headwinds through deeper domestic market penetration and improved traction in local opportunities. The quarter's performance underscores the resilience of our operating model and the strength of our diversified service portfolio.*

During the quarter, we successfully completed a regulatory audit from Ukraine, reaffirming our continued focus on quality and compliance. We also commenced operations in Biologics contract research and development services (CRADS), marking an important addition to our capabilities.

Looking ahead, we remain optimistic about industry prospects and evolving business opportunities, supported by our strong capabilities, customer-centric approach, and expanding service portfolio."

Key Result Highlights for the Q1 FY27:

Q1 FY27

- ✓ Total Income for Q1 FY27 was at ₹1,129 Mn
- ✓ EBITDA for Q1 FY27 was ₹411 Mn; EBITDA margin was at 36.4%
- ✓ PBT for Q1 FY27 was at ₹283 Mn
- ✓ Q1 FY27 PAT was at ₹210 Mn; PAT margin was at 18.6%
- ✓ Basic EPS in Q1 FY27 was ₹4.7

Vimta
Driven by Quality. Inspired by Science.

ABOUT VIMTA LABS LIMITED:

Founded in 1984 with headquarters in Hyderabad, India, VIMTA LABS LTD., is a leading contract research and testing organization, providing food, agri, bio/pharmaceutical, medical device, speciality chemical, and electronics companies an integrated scientific, technical, and regulatory expertise to support all stages of product development and manufacturing process. Vimta also provides environmental assessments and testing services.

CAUTIONARY STATEMENT:

This press release may contain certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Vimta Labs Limited has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

Investor Relations at Vimta Labs	Registered Office
Siva Kambhampati (Chief Financial Officer) Siva.Kambhampati@Vimta.com **Ernst & Young** Siddesh Chawan Siddesh.Chawan@in.ey.com Advait Bhadekar Advait.bhadekar@in.ey.com	Plot Number 142, IDA Phase 2, Cherlapally, Hyderabad Telangana, India. 500051 CIN: L24110TG1990PLC011977 ISIN: INE579C01029 NSE Code: VIMTALABS BSE CODE: 524394 Website: www.vimta.com